Clinical trial Recruiting at 1 site Early Phase 1 Interventional Ages 18 to 55

Imaging interactions between stress hormones and opioid receptors in cocaine use disorder

Official title: Imaging Corticotrophin-releasing Factor (CRF) X Nociceptive Opioid Peptide (NOP) Interactions in Cocaine Use Disorders (Aim 1)

Run by University of Pittsburgh · NCT05008146 · Data updated 2026-11-12

This study is testing how stress hormones and certain brain receptors interact in people with cocaine use disorder to see if these interactions can help predict relapse.

More Cocaine Use Disorder trials

Quick facts

PhaseEarly Phase 1
Study typeInterventional
Ages18 Years to 55 Years
SexAll
Enrollment80 (estimated)
SponsorUniversity of Pittsburgh
Academic / other
Locations1 site (Pittsburgh, Pennsylvania)
StatusRecruiting
StartedDecember 31, 2020
Main results expectedSeptember 1, 2028
Study endsSeptember 1, 2028
Registry record updatedJuly 6, 2026
Trial IDNCT05008146 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are males and females aged 18 to 55 who meet DSM-5 criteria for cocaine use disorder without other psychiatric or addictive disorders.

Probably not a fit

Patients with current or past severe medical, endocrine, or neurological illnesses, or those with other significant psychiatric disorders may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study utilizes [C-11]NOP-1A positron emission tomography (PET) to investigate the interactions between nociceptive opioid peptide (NOP) receptors and cortisol/corticotrophin releasing factor (CRF) in individuals with cocaine use disorder (CUD) and healthy controls. It aims to understand how these interactions may predict relapse in CUD patients by examining neurochemical changes associated with stress and resilience. Participants will undergo baseline and post-hydrocortisone PET scans to assess NOP receptor binding and its response to stress. The findings could provide insights into the neurobiological mechanisms underlying relapse in CUD.

Why it matters

Potential benefit: If successful, this study could lead to the development of targeted medications to prevent relapse in individuals with cocaine use disorder.

How similar studies have gone: While studies have explored neurochemical mechanisms in addiction, this specific approach using NOP receptor imaging in CUD is relatively novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Cocaine use disorders (CUD)

1. Males or females between 18 and 55 years old
2. Fulfil DSM-5 criteria for cocaine use disorder
3. No other current DSM-5 psychiatric or addictive disorders (such as major depressive disorder, bipolar disorders, psychotic disorders, etc.,)
4. No current abuse (six months) of opiates, sedative-hypnotics, amphetamines, MDMA, etc., as well as moderate to severe alcohol or cannabis use (twice a week). Nicotine use will be quantified and controlled between groups using the Fagerstrom Test for Nicotine Dependence (Heatherton et al., 1991);
5. Not currently on prescription medical or psychotropic medications
6. No current or past severe medical, endocrine or neurological illnesses including glaucoma, seizure disorders, hypertension, hypercholesterolemia as assessed by a complete medical history and physical
7. Not currently pregnant or breastfeeding
8. No history of significant radioactivity exposure in past year from another research study or occupation that exceeds RDRC guidelines
9. No metallic objects in the body that are contraindicated for MRI

Healthy Controls (HC)

1. Males or females between 18 and 55 years old
2. No present or past DSM-5 disorders (other than nicotine dependence)
3. Criteria 5 to 9 as listed previously.

Where it's running

  • University of Pittsburgh
    Pittsburgh, Pennsylvania, United States
    Recruiting

Study contacts

  • Principal investigator: Rajesh Narendran, MD — University of Pittsburgh
  • Study coordinator: Rajesh Narendran, MD
  • Email: narendranr@upmc.edu
  • Phone: 4126475176

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.